TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Unresectable Stage III or Stage IV melanoma~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Brain metastases with symptoms or requiring treatment~* History of autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Ipilimumab (3 mg/kg) (Type: EXPERIMENTAL): Ipilimumab 3 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
- Arm 2: Ipilimumab (10 mg/kg) (Type: EXPERIMENTAL): Ipilimumab 10 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minimizing Harm From ADEs by Improving Nurse-Physician Communication

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Providers who are working in the VA on the inpatient setting, including pharmacists, nurses, and physicians.~Exclusion Criteria:~Staff who have worked at the VA less than 1 year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- VA Physicians (Type: None): VA providers who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
- VA Nurses (Type: None): VA nurses who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
- VA Pharmacists (Type: None): VA pharmacists who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Adults must have a diagnosis of HS for at least 1 year prior to Baseline.~* HS lesions must be present in at least two distinct anatomical areas, one of which must be at least Hurley Stage II or Hurley Stage III.~* Subject must have stable HS for at least 60 days prior to Screening visit and at Baseline visit.~* Subject must have experienced an inadequate response to at least a 90-day treatment of oral antibiotics for treatment of HS.~* Subject must have a total AN count of greater than or equal to 3 at baseline.~Exclusion Criteria:~* Subject was previously treated with adalimumab or another anti-tumor necrosis factor (anti-TNF) therapy (e.g., infliximab or etanercept).~* Subjects on permitted oral antibiotic treatment for HS who have not been on a stable dose for at least 28 days prior to the Baseline visit.~* Subject received oral concomitant analgesics (including opioids) for HS-related pain within 14 days prior to Baseline visit.~* If entering the study on concomitant oral analgesics for non-HS related pain:~  * Subject on opioid analgesics within 14 days prior to Baseline visit;~ * Subject not on a stable dose of non-opioid oral analgesics for at least 14 days prior to the Baseline visit (as needed is not considered a stable dose).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 12 weeks.
- Adalimumab Every Week (EW) (Type: EXPERIMENTAL): Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
- Placebo/Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to receive placebo in Period 1 received placebo every week from Week 12 to Week 35 in Period 2 (up to 24 weeks).
- Adalimumab Every Week (EW)/Placebo (Type: EXPERIMENTAL): Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
- Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW) (Type: EXPERIMENTAL): Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
- Adalimumab Every Week (EW)/Adalimumab Every Week (EW) (Type: EXPERIMENTAL): Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medium-term Health Coaching and Life-long Monitoring in Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* T2DM diagnosed \> 3 months prior to the enrollment~* HbA1c \>= 6,5 %~* Capability of filling questionnaires by their own language~* Being able to use the devices provided~* Being cognitively able to participate~Exclusion Criteria:

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): treatment as usual
- Self-monitoring for patients with Diabetes mellitus type 2 (Type: EXPERIMENTAL): Patients are self-monitoring and submitting their vital parameters.
- Nurse-monitoring for patients with Diabetes mellitus type 2 (Type: EXPERIMENTAL): Nurses are measuring and entering the vital parameters of the patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Grade \>= 2 cutaneous and/or subcutaneous fibrosis (NCI-CTCAE v4 toxicities scale) revealed from 6 to 24 months after head and neck radiotherapy.~2. Head and neck cancers treated by radiation therapy +/- chemotherapy, +/- surgery, with no evidence of progressive disease.~3. Age \>= 18~4. Karnofsky PS ≥ 70~5. normal renal function (plasmatic creatinine \<= 130 micromol/l), normal cholesterol, normal hepatic function (total bilirubin \<= 1.5 UNL, SGOT and SGPT \<= 2 UNL)~6. Written informed consent of the patient.~Exclusion Criteria:~1. any chronic treatment by corticoids~2. severe cardiac pathology~3. patients already treated by statins or treated by fibrates, cyclosporine~4. history of muscular toxicities when treated by fibrates or by statins~5. Personal or familial history of hereditary muscular pathology~6. Plasmatic CPK \>3 UNL~7. patient already included in another therapeutic trial with an experimental drug,~8. pregnant patient or susceptible to pregnancy or breast feeding (patients in age to give birth must be placed under efficient contraception),~9. a social or psychological condition that does not allow a positive patient's participation in the treatment and necessary medical follow-up to be envisaged,~10. the patient is under legal restrained or tutelage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pravastatin (Type: EXPERIMENTAL): Pravastatin : 40mg/day during 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with Chronic Kidney Disease (CKD) has been on hemodialysis 3 times per week~* Patient receiving treatment for itch~* Patient has a baseline NRS score \> 4~Exclusion Criteria:~* Patient has pruritus cause other than CKD or its complications~* Patients has hepatic cirrhosis~* Patient has a known history of allergic reaction to opiates

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MR13A9/MR13A9 (Type: EXPERIMENTAL): Patients are administered MR13A9 for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
- Placebo/MR13A9 (Type: PLACEBO_COMPARATOR): Patients are administered Placebo for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Patients \>=18 years with type 2 diabetes~2. HbA1c of \>= 7.0% (53 mmol/mol) and =\< 10% (86 mmol/mol)~3. Mean seated systolic blood pressure 130-159 mmHg and diastolic blood pressure 80-99 mmHg~Exclusion criteria:~1. Uncontrolled hyperglycaemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast before randomization~2. Known or suspected secondary hypertension~3. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or transient ischemic attack within 3 months prior to informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): BI 10773 low dose once daily
- BI 10773 high dose (Type: EXPERIMENTAL): BI 10773 high dose once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching BI 10773

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertension patients not included exclusion criteria~* Mean seated SBP ≥140mmHg in patients with newly Diagnosed~Exclusion Criteria:~- msDBP≥110mmHg or ms SBP ≥ 180mmHg at the screening and randomization visit

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Losartan 50mg/amlodipine 5mg (Type: EXPERIMENTAL): Once daily, 1T, PO medication
- Losartan 100mg/amlodipine 5mg (Type: EXPERIMENTAL): Once daily, 1T, PO medication
- Losartan50 mg/Hydrochlorothiazide12.5 mg (Type: ACTIVE_COMPARATOR): Once daily, 1T, PO medication
- Losartan100 mg/Hydrochlorothiazide25 mg (Type: ACTIVE_COMPARATOR): Once daily, 1T, PO medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efalizumab to Treat Uveitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is 18 years of age or older;~* Participant has a diagnosis of sight-threatening, intermediate or posterior uveitis of at least three months duration prior to original enrollment that is causing persistent cystoid macular edema in one or both eyes. Their disease requires treatment to control their intraocular inflammatory disease with at least 20 mg/day of prednisone (or equivalent) or any combination of two or more anti-inflammatory treatments for uveitis, including for example prednisone, cyclophosphamide, cyclosporine, azathioprine, mycophenolate mofetil, methotrexate, etc.~* Participant exhibits intolerance to the indicated systemic medications required for their uveitis or, though their uveitis may be under control, wish to be taken off their present medications due to potential or actual unacceptable side effects.~* Participant has visual acuity in at least one eye of 20/200 or better.~* Participant has normal renal or liver function or no worse than mild abnormalities as defined by the Common Toxicity Criteria.~* Participant is not currently pregnant or lactating.~* Both men and women with reproductive potential and who are sexually active agree to use acceptable birth control methods throughout the course of the study and for six weeks following the last administration of the study medication.~* Participant must have the ability to understand and sign an informed consent form.~Exclusion Criteria:~* Participants who had received previous treatment with an intercellular adhesion molecule (ICAM) or lymphocyte function-associated antigen-1 (LFA-1) directed monoclonal antibody or any other investigational agent that would interfere with the ability to evaluate the safety, efficacy or pharmacokinetics of efalizumab.~* Participant has a significant active infection.~* Participant has a history of cancer (other than a non-melanoma skin cancer) diagnosed within the past 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Efalizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Poliovirus Vaccine Trial in Bangladesh

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants of 6 weeks of age (±2 days).~* Study families reside within the Health and Demographic Surveillance System (HDSS) area, service area of the ICDDR,B.~* Family able to understand and comply with planned study procedures~Exclusion Criteria:~* Family residence outside the ICDDR,B HDSS service area, or families expecting to move away during the study period, will be excluded.~* A diagnosis or suspicion of immunodeficiency disorder (either in the infant or in a member of the immediate family).~* A diagnosis or suspicion of bleeding disorder that would contraindicate venipuncture.~* Acute diarrhea, infection or illness at the time of the first visit (6 weeks of age) that would require infant's admission to a hospital or would contraindicate provision of OPV per country guidelines.~* Acute vomiting and intolerance to liquids within 24 hours before the first visit (6 weeks of age).~* Receipt of OPV or IPV at any time before enrollment based upon mother's recall or immunization card if available.~* Because of contact transmission of vaccine poliovirus strains, newborns from multiple births will be excluded from the study to prevent transmission of vaccine strains received during routine immunization from the twin to the study participant.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 6 Weeks
- Healthy Volunteers: t

Study Arms:
- Bivalent OPV 2 week interval (Type: ACTIVE_COMPARATOR): Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
- Bivalent OPV 4 week interval (Type: ACTIVE_COMPARATOR): Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
- Monovalent OPV 2week interval (Type: ACTIVE_COMPARATOR): Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
- Monovalent OPV 4 week interval (Type: ACTIVE_COMPARATOR): Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
- Trivalent OPV 4 week interval (Type: ACTIVE_COMPARATOR): Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STEMI and Incretins Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~aged \>18, first STEMI, STEMI with multi vessels coronary stenosis.~Exclusion Criteria:~aged \< 18, renal impairment, mono vessel STEMI, severe depression of left ventricle ejection fraction (LVEF \<35%).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- diabetics STEMI (Type: None): Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
- non diabetics STEMI (Type: None): Non diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis(Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
- diabetics incretin-users STEMI (Type: None): Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These patients were treated by incretin therapy at last 6 months before study enrollment.
- diabetics never-incretin-users STEMI (Type: None): Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These diabetic patients were never treated by incretin therapy before study enrollment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
A subject must meet all of the following criteria to be eligible for the trial:~Inclusion Criteria:~* Be 18-70 years of age, inclusive~* Able to comprehend and follow all required study procedures and be available for all visits scheduled in the study~* If a woman is of childbearing potential, she must consistently use an acceptable method of contraception or confirm in writing she will abstain from sexual activity from the Screening Visit through Week 28.~* Able and willing to provide informed consent~A subject with any one of the following criteria is not eligible for the trial:~Exclusion Criteria:~* Previous receipt of any hepatitis B vaccine~* History of hepatitis B or human immunodeficiency virus (HIV) infection or positive test for HBsAg, anti-HBs, antibody to hepatitis B core antigen (anti-HBc), or antibody to HIV~* History of autoimmune disorder~* History of sensitivity to any component of study vaccines~* Has received the following prior to the first injection:~  1. Within 28 days:~     * Any vaccine~    * Systemic corticosteroids (more than 3 consecutive days) or other immunomodulators or immune suppressive medication~    * Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF)~    * Any other investigational medicinal agent~ 2. Within 90 days: Blood products or immunoglobulin~ 3. At any time: An injection of DNA plasmids or oligonucleotide~* If female: Pregnant, nursing, or planning to become pregnant during the trial~* Is undergoing chemotherapy or expected to receive chemotherapy during the study period; has a diagnosis of cancer within the last 5 years other than squamous or basal cell carcinoma of the skin~* Any other medical condition considered by the investigator likely to interfere with the subject's compliance or the interpretation of study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- HEPLISAV (Type: EXPERIMENTAL): 0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.
- Engerix-B (Type: ACTIVE_COMPARATOR): 1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete